Table 1.
Fistula-associated anal adenocarcinoma in 15 patients.
| Patient | Gender | Age (y) | Fistula duration (y) | Histological type | Stage | Treatment | Time of follow-up (months) | Outcome |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 56 | 20 | AD | T3N1M0 | APR + postoperative chemotherapy | 18 | Death |
| 2 | F | 52 | 2 | AD | T2N0M0 | APR | 6 | Alive |
| 3 | M | 41 | 10 | MA | T2N0M0 | APR + postoperative chemotherapy |
17 | Alive |
| 4 | M | 58 | 10 | AD | T2N2M0 | CRT | 11 | Recurrence |
| 5 | M | 47 | 0.75 | MA | T3N0M0 | APR + postoperative chemotherapy | 18 | Alive |
| 6 | M | 32 | 3.75 | MA | T3N0M0 | APR + postoperative chemotherapy | 15 | Recurrence |
| 7 | M | 55 | 2 | MA | T2N0M0 | APR + postoperative chemotherapy | 44 | Alive |
| 8 | M | 52 | 15 | MA | T3N0M0 | CRT | 36 | Death |
| 9 | M | 59 | 3 | MA | T3N0M0 | CRT | 30 | Death |
| 10 | M | 61 | 12 | MA | T3N2M0 | No treatment | 6 | Death |
| 11 | M | 65 | 5 | MA | T3N0M0 | Local resection + CRT | 74 | Alive |
| 12 | M | 72 | 30 | MA | T2N0M0 | APR | 47 | Alive |
| 13 | M | 55 | 15 | MA | T4N3M1 | Palliative colostomy | 1 | Alive |
| 14 | M | 61 | 1 | MA | T3N2M0 | On NACRT | 5 | Alive |
| 15 | M | 51 | 2 | MA | T2N0M0 | APR + postoperative chemotherapy | 1 | Alive |
M, male; F, female; AD, adenocarcinoma; MA, mucinous adenocarcinoma; APR, abdominoperineal resection; CRT, chemoradiotherapy; NACRT, neoadjuvant chemoradiotherapy.